Literature DB >> 26755129

Continuous low-dose feeding of highly active pharmaceutical ingredients in hot-melt extrusion.

Marcos Llusa1, Stefan Mohr1, Ramona Baumgartner1, Amrit Paudel1, Gerold Koscher1, Johannes Khinast1,2.   

Abstract

CONTEXT: Manufacturing solid low-dose pharmaceutical products has always the homogeneity challenge. In continuous manufacturing, there is the additional challenge of feeding active pharmaceutical ingredient (API) dry powder at low rates. This paper presents a method for feeding API particles into a continuous extrusion process using a suspension. The challenges for feeding and the product homogeneity are both addressed.
OBJECTIVE: The objective of this study is to demonstrate the feasibility of manufacturing low-dose extrudates by feeding the API particles in a diluted anti-solvent suspension.
MATERIALS AND METHODS: Extrudates with an Ibuprofen content of 0.021% and 0.043% (w/w) were prepared by feeding a 0.9% w/w suspension of Ibuprofen particles into a Coperion extruder. RESULTS AND DISCUSSION: The homogeneity (RSD) of extrudates was tested during a time span of 30 min and had values between 2% and 7%.
CONCLUSION: Feeding particles in an anti-solvent suspension offers a simple feeding option for API and minor components which yield products of desired homogeneity. The liquid feeding approach offers a simplified process with enhanced process control possibilities.

Entities:  

Keywords:  API homogeneity; continuous manufacturing; hot-melt extrusion; liquid feeding; low-dose solid products

Mesh:

Substances:

Year:  2016        PMID: 26755129     DOI: 10.3109/03639045.2015.1135938

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  1 in total

1.  Precise Dosing of Pramipexole for Low-Dosed Filament Production by Hot Melt Extrusion Applying Various Feeding Methods.

Authors:  Rebecca Chamberlain; Hellen Windolf; Simon Geissler; Julian Quodbach; Jörg Breitkreutz
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.